Your session is about to expire
← Back to Search
Monoclonal Antibodies
Iodine-131 Anti-B1 Antibody for Non-Hodgkin's Lymphoma
N/A
Waitlist Available
Research Sponsored by Corixa Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients must have a histologically confirmed diagnosis of low-grade NHL or transformed low-grade NHL according to International Working Formulation for Clinical Usage (including small lymphocytic, follicular small cleaved, and follicular mixed small-cleaved and large cell [<50% large cell component]). Tumor must be positive for CD20 antigen.
Patients must have been treated with at least one chemotherapy regimen and have relapsed or progressed, or failed to achieve an objective response (CR or PR) on their last chemotherapy regimen.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is testing Iodine-131 Anti-B1 Antibody to see if it is safe and effective.
Who is the study for?
This trial is for patients with low-grade Non-Hodgkin's Lymphoma (NHL) who've had at least one chemo treatment but didn't get better or relapsed. They must have a decent performance status, expected to live at least 3 months, and their major organs should be functioning well. Pregnant women, those with serious illnesses like heart disease or HIV, and anyone who has received certain treatments recently can't join.Check my eligibility
What is being tested?
The study aims to provide broader access to Iodine-131 Anti-B1 Antibody for NHL patients and gather more data on its effectiveness and safety. Participants will receive this antibody that targets CD20 antigen-positive tumors in individuals whose cancer returned or didn’t respond after chemotherapy.See study design
What are the potential side effects?
While the specific side effects are not listed here, similar therapies often cause symptoms related to radiation exposure such as fatigue, nausea, and lowered blood cell counts which could increase infection risk. Organ function may also be affected.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My lymphoma is low-grade or transformed low-grade and CD20 positive.
Select...
My cancer returned or didn't respond after my last chemotherapy.
Select...
My blood counts are within the required range and I don't need regular blood transfusions or growth factor injections.
Select...
My kidney, liver, and enzyme levels are within the required range.
Select...
I can care for myself and am expected to live at least 3 more months.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Corixa CorporationLead Sponsor
9 Previous Clinical Trials
590 Total Patients Enrolled
GlaxoSmithKlineIndustry Sponsor
4,750 Previous Clinical Trials
8,067,452 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't had chemotherapy, radiation, immunotherapy, or steroids recently.I am not pregnant or nursing and agree to use birth control during and for 6 months after treatment.More than 25% of my bone marrow space is affected by lymphoma.I do not have severe heart disease or other serious illnesses that would prevent me from being evaluated.My cancer returned or didn't respond after my last chemotherapy.My blood counts are within the required range and I don't need regular blood transfusions or growth factor injections.My kidney, liver, and enzyme levels are within the required range.I had cancer other than lymphoma but have been cancer-free for over 5 years, except for certain skin cancers or in situ cervical cancer.My cancer got worse within a year after receiving high-dose radiation.I am currently taking medication for cancer, either approved or experimental.I have cancer that has spread to my brain or its coverings.My lymphoma is low-grade or transformed low-grade and CD20 positive.I have undergone radioimmunotherapy before.I have had a stem cell or bone marrow transplant.I can care for myself and am expected to live at least 3 more months.I have a kidney condition that blocks urine flow.I am not currently on IV antibiotics for an infection.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any available slots for individuals to join this clinical trial?
"This clinical study, which was initially published on September 1st 1998 and last modified on June 23rd 2005, is no longer enrolling patients. However, there are over 1700 other trials currently recruiting volunteers for their research."
Answered by AI
Are individuals above the age of eighteen allowed to participate in this trial?
"To be eligible to participate in this trial, individuals must meet the age requirement of being over 18 years old and younger than 0."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger